[6-K] GSK plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

GSK plc announced the third tranche of its previously declared £2.0 billion share buyback programme: an additional tranche of up to £0.3 billion commencing 30 September 2025 and expected to complete by 19 December 2025. Purchases will be executed under a non-discretionary agreement with BNP Paribas and any Ordinary Shares bought under this tranche will be held as Treasury shares. The Programme is being implemented within GSK's existing repurchase authority of up to 413,957,879 Ordinary Shares and in accordance with applicable market regulations. No repurchases will be made in the United States or for American Depositary Receipts.

Positive

• Third tranche of up to £0.3bn announced, progressing the previously disclosed £2.0bn buyback programme
• Repurchased shares to be held as Treasury shares, reducing outstanding share count and supporting EPS
• Execution via non-discretionary agreement with BNP Paribas and on regulated exchanges, indicating procedural controls
• Tranche falls within AGM-authorised repurchase limit of 413,957,879 Ordinary Shares

Negative

• No repurchases will be made in the United States or in respect of American Depositary Receipts, limiting return to ADR holders
• Tranche size (£0.3bn) is modest relative to the full £2.0bn programme and may have limited near-term market impact

Insights

Financial Analyst

TL;DR: A routine capital return that should modestly boost EPS; tranche size is small relative to the full £2.0bn programme.

GSK's announcement confirms continuation of a planned £2.0 billion repurchase programme with a third tranche of up to £0.3 billion executed via BNPP and completed by 19 December 2025. Holding repurchased Ordinary Shares as Treasury shares reduces outstanding share count and is expected to enhance reported earnings per share, all else equal. The tranche sits within the company’s existing AGM-authorised limit and will follow market abuse and FCA rules, limiting execution risk from a governance and regulatory perspective.

Corporate Governance Expert

TL;DR: Structured, compliant repurchase using an independent broker aligns with best practices and shareholder-return objectives.

The use of a non-discretionary agreement with BNP Paribas, execution on regulated UK venues, and adherence to pre-set parameters demonstrate procedural controls consistent with governance norms for buybacks. The decision to hold shares as Treasury rather than cancelling immediately preserves flexibility for future use, such as employee plans. The explicit exclusion of US/ADR repurchases is a disclosure clarity point, ensuring cross-jurisdictional compliance considerations are addressed.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 30 September 2025, London UK

GSK plc announces the third tranche of share buyback programme

On 24 February 2025, GSK plc ("GSK") announced the commencement of a £2 billion share buyback programme (the "Programme"), as announced in its 2024 full year results announcement published on 5 February 2025. The Programme is to be implemented over the period to the end of Q2 2026.

The first tranche of the Programme (of up to £0.7 billion) commenced on 24 February 2025 and completed on 3 June 2025, in accordance with its terms. The second tranche of the Programme (of up to £0.45 billion) commenced on 4 June 2025 and completed on 18 September 2025, in accordance with its terms.

GSK announces that the third tranche of the Programme of up to £0.3 billion will commence today.

GSK has entered into a non-discretionary agreement with BNP Paribas S.A. ("BNPP"), enabling GSK to buy back ordinary shares of 31¼ pence each in GSK ("Ordinary Shares") with an aggregate value of up to £0.3 billion (the "Third Tranche"). Purchases of Ordinary Shares under the Third Tranche are expected to commence on 30 September 2025 and to be completed by 19 December 2025.

The purpose of the Programme is to return excess capital to shareholders and reduce the share capital of the company, and it is expected that the implementation of the Programme will enhance earnings per share. Ordinary Shares purchased under the Third Tranche will be held as Treasury shares.

BNPP will make trading decisions in relation to the Third Tranche independently of GSK with regard to the timing of purchases. Any purchase of Ordinary Shares by BNPP contemplated by this announcement will be carried out on the London Stock Exchange and/or Cboe Europe Limited through the BXE and CXE order books. Any purchases of Ordinary Shares by GSK from BNPP under the Third Tranche will be carried out on the London Stock Exchange.

The Third Tranche will be effected within certain pre-set parameters and in accordance with GSK's general authority to repurchase shares and will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014, the Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) as well as applicable laws and the regulations of the UK Financial Conduct Authority (including Chapter 9 of the Listing Rules).

The Third Tranche will occur within the limitations of GSK's existing general authority to repurchase up to 413,957,879 Ordinary Shares granted at its 2025 Annual General Meeting.

No repurchases will be made in the United States of America or in respect of GSK's American Depositary Receipts.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK enquiries
Media:	Simon Steel	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q2 Results for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: September 30, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What is the size and timing of GSK's third buyback tranche (GLAXF)?

GSK announced a third tranche of up to £0.3 billion, expected to commence on 30 September 2025 and complete by 19 December 2025.

How will GSK execute purchases under the third tranche?

GSK has a non-discretionary agreement with BNP Paribas, with purchases carried out on the London Stock Exchange and/or Cboe Europe venues.

Will repurchased GSK shares be cancelled or held?

Ordinary Shares repurchased under the third tranche will be held as Treasury shares.

Does this tranche fit within GSK's authorised repurchase limit?

Yes. The third tranche will be effected within GSK's existing general authority to repurchase up to 413,957,879 Ordinary Shares.

Will GSK repurchase shares in the U.S. or buy ADRs?

No. The announcement states no repurchases will be made in the United States or in respect of GSK's American Depositary Receipts.